chr19-12891965-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000159.4(GCDH):c.262C>T(p.Arg88Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000539 in 1,614,102 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R88H) has been classified as Pathogenic.
Frequency
Consequence
NM_000159.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GCDH | NM_000159.4 | c.262C>T | p.Arg88Cys | missense_variant | 4/12 | ENST00000222214.10 | NP_000150.1 | |
GCDH | NM_013976.5 | c.262C>T | p.Arg88Cys | missense_variant | 4/12 | NP_039663.1 | ||
GCDH | NR_102316.1 | n.370C>T | non_coding_transcript_exon_variant | 4/12 | ||||
GCDH | NR_102317.1 | n.678C>T | non_coding_transcript_exon_variant | 3/11 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152210Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000477 AC: 12AN: 251424Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135900
GnomAD4 exome AF: 0.0000520 AC: 76AN: 1461892Hom.: 0 Cov.: 33 AF XY: 0.0000633 AC XY: 46AN XY: 727248
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152210Hom.: 0 Cov.: 32 AF XY: 0.0000672 AC XY: 5AN XY: 74354
ClinVar
Submissions by phenotype
Glutaric aciduria, type 1 Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 19, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 88 of the GCDH protein (p.Arg88Cys). This variant is present in population databases (rs142967670, gnomAD 0.01%). This missense change has been observed in individual(s) with glutaric aciduria type I (PMID: 8900227, 10699052, 11073722, 19433437, 23395213, 28438223). ClinVar contains an entry for this variant (Variation ID: 189150). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GCDH protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects GCDH function (PMID: 8900227). This variant disrupts the p.Arg88 amino acid residue in GCDH. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21811973, 23395213, 24332224). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 30, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Nov 14, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 06, 2017 | Variant summary: The GCDH c.262C>T (p.Arg88Cys) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 6/121308 control chromosomes at a frequency of 0.0000495, which does not exceed the estimated maximal expected allele frequency of a pathogenic GCDH variant (0.0035355). The variant was reported in numerous affected individuals in the literature and functional studies using both expression systems as well as patient firbroblasts show the variant to have a complete loss of GCDH activity (Biery_1996, CHRISTENSEN_2004). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic/pathogenic. Taken together, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 16, 2018 | Across a selection of the available literature, the GCDH c.262C>T (p.Arg88Cys) variant has been identified in ten probands with glutaric acidemia, including four who carried the variant in a homozygous state and six who carried the variant in a compound heterozygous state, and in an additional seven proband alleles (Biery et al. 1996; Schwartz et al. 1998; Busquets et al. 2000; Zschocke et al. 2000; Al-Dirbashi et al. 2011; Bhattacharjee et al. 2015; Schmiesing et al. 2017). Control data are unavailable for this variant, which is reported at a frequency of 0.000108 in the European (non-Finnish) population of the Genome Aggregation Database. Expression of wild type and p.Arg88Cys variant GCDH in E. coli revealed the p.Arg88Cys variant produced stable protein, however Western blotting found no enzyme activity (Biery et al. 1996). Expression of the p.Arg88Cys variant in HeLa cells revealed expression and degradation rates similar to wild type and normal mitochondrial localization but abnormal mitochondrial architecture, while expression in HEK293T cells revealed no negative impact on oligomer formation (Schmiesing et al. 2017). Based on the collective evidence, the p.Arg88Cys variant is classified as pathogenic for glutaric acidemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 24, 2020 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 13, 2022 | Published functional studies demonstrate this variant results in glutaryl-CoA dehydrogenase activity that is less than 1% of the activity of expressed wild-type protein (Biery et al., 1996); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 25255367, 24332224, 23395213, 25087612, 28438223, 28062662, 8900227, 10699052, 11073722, 19433437, 31536184, 33064266, 32778825) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at